Form 4: Unicycive Therapeutics Executive Pramod Gupta Reports Stock Option Grant and Beneficial Ownership
SEC Form 4
Pramod Gupta, EVP of Pharmaceuticals and BD at Unicycive Therapeutics, reports the acquisition of stock options and updates to beneficial ownership.
Summary
- On August 12, 2024, Pramod Gupta, EVP of Pharmaceuticals and BD at Unicycive Therapeutics, acquired 81,750 stock options with an exercise price of $0.34.
- These options vest over time, with 20,438 vesting on August 12, 2025, and the remainder vesting monthly thereafter.
- Following the reported transaction, Gupta directly owns 2,119,862 shares of common stock.
- The options expire on August 12, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither particularly positive nor negative on its own.
Positives
- The acquisition of stock options by a key executive may indicate confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting changes in beneficial ownership by a company insider. Such filings are common and provide transparency to the market.
Stakeholder Impact
- The change in beneficial ownership may be of interest to shareholders.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of stock option transaction. |
| 08/12/2025 | Date when 20,438 of the stock options vest. |
| 08/12/2034 | Expiration date of the stock options. |
| 08/14/2024 | Date of signature on the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.